Program
apecotrep
Also written as “BI 764198”, “BI 764198 - Formula A” and “BI 764198 - Formula B”.
In Boehringer Ingelheim's pipeline, TRPC6 inhibitor
. Its studies are mostly in Renal Insufficiency, Chronic · Glomerulosclerosis, Focal Segmental · COVID-19, led by Boehringer Ingelheim.
Furthest: phase 3, since Oct 22, 202513 company-led studies, 2 open or runningNext primary completion: Jan 20, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 132 open or running | phase 3since Oct 22, 2025 | Feb 25, 2019 | Jan 20, 2028phase 2 · NCT07355296 |
- Named in Boehringer Ingelheim’s own pipeline as
Apecotrep (BI 764198)
, phase 3, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 25, 2019First study: phase 1 study in HealthyFirst studyNCT03854552 · 72 enrolled · Germany
- Sep 24, 2019Phase 1 study in HealthyNCT04102462 · 52 enrolled · Germany
- Nov 22, 2019Phase 1 study in Renal Insufficiency, ChronicNCT04176536 · 28 enrolled · Germany
- Oct 26, 2020Phase 2 study in COVID-19NCT04604184 · 133 enrolled · United States, Brazil, Chile and more
- Dec 1, 20202 phase 1 studies in HealthyNCT04656288, NCT04665700
- Jan 27, 2022Phase 2 study in Renal Insufficiency, ChronicNCT05213624 · 67 enrolled · United States, Australia, Belgium and more
- Apr 25, 2023Phase 1 study in HealthyNCT05863130 · 24 enrolled · Netherlands
- Apr 25, 2025Phase 1 study in HealthyNCT06955754 · 16 enrolled · Germany
- Oct 22, 2025Phase 3 study in Glomerulosclerosis, Focal SegmentalNCT07220083 · 286 planned · United States, Argentina, Australia and more
- Dec 17, 2025Phase 1 study in HealthyNCT07308652 · 14 enrolled · Germany
- Jan 20, 2026Phase 1 study in HealthyNCT07368569 · 14 enrolled · Germany
- Jan 20, 2026Phase 2 study in Proteinuric Kidney DiseasesNCT07355296 · 132 planned · United States, Argentina, Australia and more
Ahead
- Jan 20, 2028Primary completion: phase 2 study in Proteinuric Kidney DiseasesNCT07355296
- Dec 27, 2028Primary completion: phase 3 study in Glomerulosclerosis, Focal SegmentalNCT07220083
TargetBeta
“TRPC6 inhibitor”the company's pipeline, read by Claude · source
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07368569Healthy · Germany | 1 | Completed | Mar 14, 2026 | 14 |
| NCT07355296Proteinuric Kidney Diseases · United States, Argentina, Australia and more | 2 | Recruiting | Jan 20, 2028 | 132 |
| NCT07308652Healthy · Germany | 1 | Completed | Mar 24, 2026 | 14 |
| NCT07220083Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more | 3 | Recruiting | Dec 27, 2028 | 286 |
| NCT06955754Healthy · Germany | 1 | Completed | Jun 26, 2025 | 16 |
| NCT05863130Healthy · Netherlands | 1 | Completed | Nov 9, 2023 | 24 |
| NCT05213624Renal Insufficiency, Chronic · United States, Australia, Belgium and more | 2 | Completed | Jan 3, 2025 | 67 |
| NCT04665700Healthy · Japan | 1 | Completed | Oct 16, 2021 | 44 |
| NCT04656288Healthy · Belgium | 1 | Completed | Mar 15, 2021 | 28 |
| NCT04604184COVID-19 · United States, Brazil, Chile and more | 2 | Terminated | Mar 24, 2021 | 133 |
| NCT04176536Renal Insufficiency, Chronic · Germany | 1 | Completed | Nov 17, 2020 | 28 |
| NCT04102462Healthy · Germany | 1 | Completed | Oct 8, 2020 | 52 |
| NCT03854552Healthy · Germany | 1 | Completed | Aug 7, 2019 | 72 |
How it is read
Names in the registry
- “BI 764198”, 10 entries
- “BI 764198 - Formula A”, 1 entry
- “BI 764198 - Formula B”, 1 entry
- “BI 764198 - Formula C”, 1 entry
- “BI 764198 - Formula D”, 1 entry
Conditions, from the studies’ own filings
- Renal Insufficiency, Chronic, 2 studies
- Glomerulosclerosis, Focal Segmental, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.